PT  - JOURNAL ARTICLE
AU  - Ning-jing LIN
AU  - Wen ZHENG
AU  - Yun-tao ZHANG
AU  - Xiao-pei WANG
AU  - Yu-qin SONG
AU  - Yan XIE
AU  - Mei-feng TU
AU  - Ling-yan PING
AU  - Jun ZHU
TI  - Clinical Analysis of 13 Cases with Burkitt Lymphoma or Burkitt-like Lymphoma
AID  - 10.1007/s11805-010-0504-1
DP  - 2010 Apr 01
TA  - Clinical Oncology and Cancer Research
PG  - 110--115
VI  - 7
IP  - 2
4099  - http://www.cancerbiomed.org/content/7/2/110.short
4100  - http://www.cancerbiomed.org/content/7/2/110.full
SO  - Cancer Biol Med2010 Apr 01; 7
AB  - OBJECTIVE To summarize the clinical characteristics and treatment effects of Burkitt lymphoma (BL) and Burkitt-like lymphoma (BLL), and to explore the best possible optimal regimens and the treatment-related complications.METHODS Clinical data of 13 BL and BLL patients, who were pathologically diagnosed and treated in the Beij ing Cancer Hospital from August 1996 to October 2008, were retrospectively analyzed. All patients received the therapeutic regimen with chemotherapy as the first-line treatment. The treatment effect and adverse reactions were evaluated.RESULTS Of the 13 patients, 12 were men and 1 was woman, with a median age of 15 years (range, 11-62). Three of the patients were in stage I, 2 in stage II, 2 in stage III, and 6 in stage IV. Advanced cases were 8 (stage III and IV), accounting for 61.5% of the patients. Bone marrow involvement was found in 2 cases (15.4%) and central nervous system invasion in 4 (30.8%) at the beginning of the treatment. The common involved sites included the superficial lymph nodes (61.5%), abdominal organs (53.8%), and abdominal and retro-peritoneal lymph nodes (38.5%). B symptoms were observed in 7 patients (53.8%). Serum lactate dehydrogenase (LDH) level was increased in 8 of the 10 patients who underwent the serum LDH determination, while serum uric acid level was increased in 1 of the 10. Pathological diagnosis showed that 11 of the cases were BL and 2 BLL. Of the 13 patients, 11 (84.6%) achieved a complete remission (CR) or CR/unconfirmed (CRu), and 1 (7.7%) a partial remission (PR), with a total responsive rate of 92.3%. At a median follow-up of 8 months (range 5-35), 6 patients were found dead at the end of the follow-up. One of the 13 patients was lost to the follow-up. The 1-year overall survival, progression-free survival, and disease-free survival rates were 56.98%, 32.31% and 39.77%, respectively. The grade-III or IV myelosuppression was found in 9 patients during the chemotherapy (69.2%), and tumor lysis syndrome and grade-IV total gastrointestinal mucositis were seen in 1.CONCLUSION Intensive short-course chemotherapy is recommended as the optimal first-line treatment for BL and BLL, and actively preventive treatments for chemotherapy-related adverse reactions are essential in the treatment course.